The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Anti-D Immunoglobulin Market In 2026 And What Value Is Projected For 2030?
The anti-d immunoglobulin market size has seen substantial growth over recent years. It is anticipated to increase from $2.59 billion in 2025 to $2.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. The expansion observed in previous periods was driven by factors such as restricted plasma donor pools, reliance on manual antibody extraction procedures, heightened awareness of hemolytic disease, expanded hospital and clinical utilization, and the adoption of intramuscular administration.
The anti-d immunoglobulin market is projected to experience robust expansion over the coming years. This market is forecast to reach $3.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the forecast period include the advancement of intravenous formulations, the spread of automated plasma fractionation technologies, an increase in antenatal screening initiatives, the growing global blood bank infrastructure, and the development of personalized immunoglobulin therapies. Key trends anticipated during the forecast timeframe encompass a surging need for anti-d immunoglobulin in managing hemolytic disease, greater uptake of pre-filled syringes and single-use vials, the broadening of antenatal and postnatal prophylaxis schemes, the expansion of hospital and blood bank distribution routes, and an increased emphasis on safety, purity, and adherence to regulations.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Anti-D Immunoglobulin Market?
The anticipated high birth rates are projected to stimulate the growth of the anti-D immunoglobulin market moving forward. Birth rates signify the yearly count of live births per 1,000 individuals within a population. These rates are rising because of limited access to educational resources and family planning services, which in turn leads to greater fertility and larger families. Anti-D immunoglobulin aids in managing birth rates by preventing Rh incompatibility during pregnancy, thereby decreasing the likelihood of hemolytic disease in newborns and promoting healthier outcomes for subsequent pregnancies. As an illustration, the Centers for Disease Control and Prevention, a US government agency, reported in April 2025 that 3,622,673 births were recorded in 2024, representing a 1% increase compared to 2023. Consequently, the elevated birth rates are a key factor driving the expansion of the anti-D immunoglobulin market. The expansion of healthcare infrastructure is set to accelerate the growth of the anti-D immunoglobulin market moving forward. Healthcare infrastructure encompasses the comprehensive system of facilities, necessary equipment, skilled workforce, and support mechanisms vital for delivering health services to a community. This infrastructure is growing as a direct result of the increasing global population, which in turn escalates the demand for medical care and necessitates the establishment of more hospitals, clinics, and related resources. Enhancements in healthcare infrastructure improve access to maternal healthcare, which allows for better screening processes and the timely administration of anti-D immunoglobulin to avert hemolytic disease in infants. For example, in May 2023, the Department of Health and Social Care, a government body in the UK, revealed plans to invest over $27 billion (£20 billion) in constructing new hospital facilities. Under the New Hospital Programme, two hospitals are already complete, five are currently under construction, and more than 20 are projected to be initiated or finalized by the close of 2023. Therefore, the expanding healthcare infrastructure is a significant impetus behind the growth of the anti-D immunoglobulin market.
What Are The Key Segments Of The Anti-D Immunoglobulin Market?
The anti-d immunoglobulin market covered in this report is segmented –
1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications
4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories
Subsegments:
1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials
2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials
Who Are The Leading Companies Operating In The Anti-D Immunoglobulin Market?
Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.
Read the full anti-d immunoglobulin market report here:
https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report
What Are The Leading Geographic Regions In The Anti-D Immunoglobulin Market?
North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anti-D Immunoglobulin Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25694&type=smp
Browse Through More Reports Similar to the Global Anti-D Immunoglobulin Market 2026, By The Business Research Company
Immunoglobulins Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report
Intravenous Immunoglobulin Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Immunoassay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model